Cassandra J Vandenberg

7PUBLICATIONS
61CO-AUTHORS
Haematological tumoursPredictive and prognostic markersMolecular targetsSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 08, 2026
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

|Nov 05, 2025
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial.

Chee Khoon Lee, Apriliana E R Kartikasari, Nirashaa T Bound

|Mar 12, 2025
Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models.

Ksenija Nesic, Katherine Rybinski, Gayanie Ratnayake

|May 04, 2023
Targeting homologous recombination deficiency in uterine leiomyosarcoma.

Genevieve Dall, Cassandra J Vandenberg, Ksenija Nesic

|Oct 07, 2022
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.

Gwo Yaw Ho, Elizabeth L Kyran, Justin Bedo

|Oct 21, 2020
Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis.

Sarah A Best, Cassandra J Vandenberg, Etna Abad

Pageof 2

Frequent Collaborators

3 joint publications

Matthew J Wakefield

3 joint publications

Justin Bedo

2 joint publications

Anthony T Papenfuss

2 joint publications

Kristy Shield-Artin